Biomarkers - Resources

18/04/24 - A blood test for the phosphorylated protein pTau-217 could be a critical step towards early diagnosis and screening of Alzheimer's disease.

Content Type

Subjects

Keywords

Diagnostics

Blood Test for Alzheimer's Granted Breakthrough Device Status by FDA

A blood test for the phosphorylated protein pTau-217 could be a critical step towards early diagnosis and screening of Alzheimer's disease.

New MND Early Diagnostic Test: a 'Game-Changer' for Research on the Disease

Detecting the aggregation of TDP-43 spells a new diagnostic tool for MND.

Biomarker Technologies

The Power of Real-World Data Analytics in Biomarker Discovery: A Game-Changer in Medical Research

Biomarker discovery in medical research traditionally relied on controlled trials. Now, Real-World Data Analytics offers a transformative approach, analyzing real-world patient data to identify new biomarkers and improve patient care.

Digital Biomarkers & Digital Pathology

Speech-Analysis Tool for the Early Detection of Alzheimer's Handed to Linus Health in Acquisition

Aural Analysis's Speech Vitals and Linus Health's expansion into linguistic analysis herald a promising era in early detection and treatment.

Biomarkers for Drug Discovery & Development

Abcam: Cancer Biomarkers Guide

Biomarkers for Drug Discovery & Development

Merck: Analyte Quarterly

Biomarkers for Drug Discovery & Development

SomaScan Assay Services

Biomarkers for Drug Discovery & Development

TruCulture@: Whole blood collection and culture system for clinical studies

Biomarkers for Drug Discovery & Development

Complex biologies, intelligently simplified.

Biomarkers for Drug Discovery & Development

Merck: Complete Biomarker Solutions

Biomarkers for Drug Discovery & Development

Multiplex Immunoassays for Idiopathic Pulmonary Fibrosis

Biomarkers for Drug Discovery & Development

SomaScan Panels

Biomarkers for Drug Discovery & Development

Almac Diagnostic Services

Biomarkers for Drug Discovery & Development

Nu.Q Discover: Streamlining Drug Development with Non-Invasive, Real-Time, Quantitative, Liquid Biopsy Immunoassays

Biomarkers for Drug Discovery & Development

Development and Validation of Five Idiopathic Pulmonary Fibrosis (IPF) Biomarker Panels Comprising 12 Immunoassays: Advancing Clinical Diagnostic, Pharmacodynamic and Disease Activity Assessments in IPF

Biomarkers for Drug Discovery & Development

Introducing SomaScan® 11K Assay

Biomarkers for Drug Discovery & Development

2024 SomaLogic UK Research Grant Award

Biomarkers for Drug Discovery & Development

SomaSignal® Tests

Biomarkers for Drug Discovery & Development

Merck: Expanding Possibilities in Animal Health

Biomarkers for Drug Discovery & Development

Merck MILLIPLEX® Multiplex Assay User Guide

Biomarkers for Drug Discovery & Development

Nu.Q Nets: Monitoring the immune system to save lives

Biomarkers for Drug Discovery & Development

Almac: Biomarkers for Biotech

Biomarkers for Drug Discovery & Development

Abcam: Antibodies that keep you moving forward

Biomarkers for Drug Discovery & Development

Immunoassays to bring your neurodegenerative therapeutics to market

Biomarkers for Drug Discovery & Development

Diagnexia Clinical Trials Pathology Services

Biomarkers for Drug Discovery & Development

Abcam: Progress happens together

Biomarkers for Clinical Development

Unveiling the Essential Criteria for Validating Clinical Biomarkers: A Comprehensive Guide

Biomarkers by Oxford Global will explore the essential criteria for validating clinical biomarkers, shedding light on the steps and challenges involved.

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.

Diagnostics

Early Diagnostic Blood Biomarker for Dementia Identified Using Proteomics

The team hopes to develop the biomarker into a test that could be used in GP surgeries. Early prediction of dementia could be a gamechanger for new Alzheimer's therapies.

Diagnostics

Investigating Biases in Diagnostics and Biomarkers: Three Case Studies

In the quest to improve diagnostics, new technologies are key, but so is overcoming entrenched bias.

Diagnostics

Machine Learning Metabolomics Approach Used to Diagnose Ovarian Cancer

Researchers have used an artificial intelligence model to analyse the metabolites of patients with or without ovarian cancer and have reported shocking accuracy of diagnosis.

Digital Biomarkers & Digital Pathology

Enhancing Patient Care: Exploring the Role of Digital Biomarkers in Patient-Centric Healthcare

Digital biomarkers, collected from wearables and apps, are reshaping patient-centered healthcare with real-time insights and personalized care. Challenges like data privacy and interoperability require collaboration between healthcare, tech, and regulators for full integration.

Diagnostics

Using Biosensors for Biomarker Identification and Validation in Lung Cancer

Advancements in biosensors, notably graphene-based ones, show promise in swiftly identifying elusive lung cancer biomarkers, potentially revolutionising early diagnosis.

Biomarkers for Clinical Development

Advancing Biomarkers and Diagnostics in Diabetes Clinical Trials

Here, we speak to Matthias von Herrath about Biomarkers US 2023 and some current trends in the industry concerning research and technological development.

Biomarkers for Clinical Development

In Conversation With... Shuang Liang, Assistant Professor at UT Southwestern Medical Centre

Here, we speak to UT Southwestern’s Shuang Liang about monitoring TREM2 as a non-invasive diagnostic biomarker for NASH.

Biomarker Technologies

Post-Event Proceedings – Biomarkers 2023

Concise and insightful summaries of presentations delivered by prominent thought leaders at Biomarkers 2023.

Biomarker Technologies

APIS Assay Technologies

Biomarker Technologies

APIS Breast Cancer Subtyping Kit

Biomarker Technologies

Bioinformatics and Software Development Solutions

Biomarker Technologies

Contract Assay Development and Manufacturing

Biomarker Technologies

Drug Discovery and Development from Concept to Clinic

Biomarker Technologies

How to Accelerate and De-Risk Drug Development in Oncology

Biomarker Technologies

Immunohistochemistry Services

Biomarker Technologies

Liquid Biopsy - Longitudinal Cell-Free Plasma

Biomarker Technologies

Spatial Transcriptomics Services

Biomarker Technologies

The Individumed Services Biobank

Biomarker Technologies

Transformative Insights from Discovery to Clinic

Biomarkers for Clinical Development

Non-Invasive Blood Tests for the Diagnosis of Liver Disease

A recent FNIH study demonstrates the effectiveness of non-invasive blood tests in diagnosing non-alcoholic steatohepatitis (NASH), potentially reducing the need for invasive liver biopsies and improving NASH diagnosis.

Biomarker Technologies

Exploring the Pivotal Role of Medical Imaging Technology in Biomarker Discovery

Digital Biomarkers & Digital Pathology

How Digital Biomarkers Can Enhance Pathologies and Patient Care

Digital biomarkers hold promise for healthcare, offering improved rare disease detection and cost reduction, with the potential for future implementation in clinical healthcare settings.

Diagnostics

Dynamic Biomarkers for Deep Immune Phenotyping in Autoimmune Disease

On-Demand Webinar featuring Dr Mo Jain, Founder & CEO of Sapient & Dr Tanya Nguyen, Head of Scientific Operations of Sapient

Biomarker Technologies

A Simple Whole Blood and Culture System for Clinical Immunology Studies

Biomarker Technologies

Big Insights, Targeted Data, and Consistent Results

Biomarker Technologies

Bioanalytical Solutions for CAR-T and NK Cell Therapies

Biomarker Technologies

Bioanalytical Solutions for Immuno-Oncology Therapeutics

Biomarker Technologies

Data-Driven Insights from a Major US Cancer-Testing Lab

Biomarker Technologies

Expand Access and Simplify Sample Management with Visium CytAssist

Biomarker Technologies

Flexible Approaches to Single Cell Imaging

Biomarker Technologies

Hyperion XTi Imaging System

Biomarker Technologies

Immune Cell-Mediated Killing of A549 Cancer Target Cells in Real-Time

Biomarker Technologies

Inside Visium Spatial Capture Technology

Biomarker Technologies

Monitoring Cell Attachment and Tight Junctions Using Assays

Biomarker Technologies

Next Level Live-Cell Kinetic and Phenotypic Assays

Biomarker Technologies

Operational Procedures for Rules-Based Medicine

Biomarker Technologies

ProtoTrials - Enhancing Human Ex Vivo Translational Outcomes

Biomarker Technologies

Reliable Biomarker Data Through Multiplexed Immunoassays

Biomarker Technologies

Research Beyond the Limits of Fluorescence

Biomarker Technologies

Scaling Comparative Lung Cancer Studies

Biomarker Technologies

Single Cell Profilin - More Samples, Less Time Constraints

Biomarker Technologies

SomaScan - A Proteomics Platform Driving Pioneering Discoveries

Biomarker Technologies

Synexa Biomarker and Bioanalytical Solutions

Digital Biomarkers & Digital Pathology

The Applications of Biomarkers in Digital Pathology and Personalised Medicine

Digital pathology could enable the integration of biomarkers to enhance therapy effectiveness, potentially improving the capabilities of pathologists through AI-powered tools.

Biomarker Technologies

The Maxpar IMC Cell Segmentation Kit

Biomarker Technologies

The Next Level of Live-Cell Analytics

Biomarker Technologies

Transforming Care for Cancer Patients

Biomarker Technologies

Unprecedented Flexibility for HTS Automated Patch Clamp

Navigating the Pharma R&D Regulatory Landscape 2023

Our ‘Navigating the Regulatory Landscape’ eBook has been designed to provide you with invaluable insights into the intricacies of regulations & policies surrounding the challenges and opportunities of Real-World Data, genome editing, biomedical informatics, manufacturing and many more.

Genomic Markers & Precision Medicine

Applications of Spatial Transcriptome Technologies for Monitoring the Molecular Mechanisms of Diseases

Spatial transcriptomics leverages omics techniques to extract transcriptome data while retaining the context of the original tissue, aiding disease research, biomarker development, and understandings of tissue structures and cellular heterogeneity.

Genomic Markers & Precision Medicine

How Multiplexing Could Increase the Availability of Blood Biomarkers for Classifying Neurodegenerative Disorders

Recent studies have used multiplex blood biomarker information from patients to distinguish individual patient subgroups for neurodegenerative diseases, helping to stratify patients by their pathology.

Genomic Markers & Precision Medicine

Patient Stratification: Leveraging Biomarkers for Precision Medicine

Biomarker Technologies

Biomarker Strategies for Monitoring the Tumour Microenvironment

Here, we discuss the development and application of multiplex immunofluorescence-based biomarker strategies to study the tumour microenvironment in lymphoma patients, exploring how these approaches can help to identify immune cell interactions.

Diagnostics

A Wearable Ultrasound Patch for the Home Detection of Breast Cancer

Researchers from MIT have developed a wearable ultrasound patch that can image breast tissue, potentially facilitating the home detection of breast cancer. The patch can be attached a bra, and shows promise in detecting small cysts.

Biomarkers for Clinical Development

N-of-1 Trials and Their Role in Improved Healthcare Outcomes

N-of-1 trials employ individualised treatments through double-blinded, randomised sequences to determine optimal approaches and enhance patient-doctor collaboration.

Genomic Markers & Precision Medicine

Diagnostic Biomarkers Identified Through Multi-Omic Approaches in Chronic Decline and Crohn’s Disease

Diagnostic biomarkers offer a crucial means of tracking disease spread and progression. Here, we explore their application in age-related diseases, as well as inflammatory diseases such as Crohn’s.

Biomarkers for Clinical Development

Challenges in Improving Patient Outcomes: Why Biomarkers Are Difficult to Commercialise

While biomarkers are integral to the identification and validation of disease treatment methods, there is a disconnect between existing validation approaches and their applications in commercialisation.

Diagnostics

Plasma Biomarkers Show Promise in CNS Trials for Alzheimer's Disease

Proteins in the brain and plasma of individuals with sporadic Alzheimer’s disease are altered, supporting the hypothesis that plasma biomarkers have utility in predicting early onset in cognitively unimpaired populations.

Biomarkers for Drug Discovery & Development

Biomarker Discovery and the Identification of the First Cancer Biomarker

In modern healthcare, biomarkers are an integral part of approaches to monitoring patient health and condition, providing researchers with a means of predicting treatment response. But what was the first biomarker to be discovered?

Diagnostics

ddPCR Approaches for Biomarker Detection and Analysis

The high sensitivity and specificity of ddPCR assays makes the approach well-suited for screening diseases and diagnosing cancer subtypes. Here, we explore some of the ways in which medical researchers are using the technology to pioneer detection of circulating biomarkers for liquid biopsies.

Diagnostics

Blood-Based Biomarkers and Liquid Biopsies in Cancer Treatment: Precision Oncology Approaches and Strategies

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer prognosis and treatment prediction.

Biomarkers for Drug Discovery & Development

High-Throughput Biomarker Discovery for Clinical Trial Optimization

On-Demand Webinar featuring Dr Mo Jain, Founder & CEO of Sapient

This webinar shares how next-generation, high throughput mass spectrometry, advanced data analysis, and population-scale data are being leveraged for robust discovery of biomarkers that can be used to align patients, disease biology, and therapeutic interventions for clinical trials.

Genomic Markers & Precision Medicine

Biomarkers in Precision Medicine Approaches for Oncology: Overcoming Obstacles to Usage and Uptake

Precision medicine involves tailoring a therapeutic to a patient’s disease: developing precision therapies require an accurate identification of therapeutic targets from available data.

Diagnostics

High Sensitivity Phenotyping of Extracellular Vesicles by Customized, Single-Molecule Assays

On-Demand Webinar featuring Marina Cretich, Senior Researcher of the National Research Council of Italy at SCITEC-CNR

Biomarkers for Clinical Development

Tumour Heterogeneity and Immune Escape: Circumventing Some of the Biggest Roadblocks in Cancer Treatment

While the complexities associated with identifying tumour state and coordinating an effective immunotherapeutic response are many, pioneering healthcare providers are rising to the challenge.

Biomarkers for Clinical Development

Biomarkers in Psychiatry for Mental Health and Wellbeing

Biomarkers in psychiatry may have the potential to overcome the challenges associated with complications such as depression, bipolar disorder, and generalised anxiety.

Biomarkers for Clinical Development

Improving Approaches for Patient Selection Using Immuno-Oncology Biomarkers

ICIs – immune checkpoint inhibitors – have changed the landscape of therapeutic treatment for cancer and improved survival rates for patients with advanced malignancies. However, the wide variability in clinical response is a significant limitation to treatment.

Biomarkers for Clinical Development

Neurodegenerative Biomarkers and Treatment Strategies for Neurodegenerative Diseases

An understanding of the complex pathologies involved in patients with neurodegenerative diseases is integral to the identification of biomarkers and potential treatment methods for individuals who suffer from Alzheimer’s, Parkinson’s, and ALS. Here, we look at the development of dedicated biomarker strategies for helping to combat neurodegeneration.

Biomarker Technologies

Interview with Simon Gao, Clinical Imaging Scientist at Genentech

Simon Gao of Genentech discusses his background in clinical imaging and the impact that AI-based approaches may have on biomarker discovery.

Biomarker Technologies

Blood Markers of Brain Health: The Simoa® Platform—Measuring CNS biomarkers in serum and plasma with ultrasensitivity

With a sensitivity many times greater than traditional ELISA methods, the Simoa® platform can measure brain biomarkers in blood, offering you another dimension of data from a readily available, non-invasive source.

Biomarker Technologies

Lung Cancer Patient Response to Immunotherapy Could be Predicted Through AI-Calculated Biomarker

Breakthroughs in the use of AI for biomarker prediction and validation of efficacy could shape future treatments for immunotherapies. In this case study, we look at its applications in validating lung cancer patient responses to treatment.

Digital Biomarkers & Digital Pathology

AI in Digital Pathology: The Applications of Explainable AI and Deep Learning Approaches in Clinical Practice

While the integration of AI in digital pathology will require a concerted push from those in the industry, the ability to rapidly process large amounts of tissue data with a high degree of accuracy makes it a potentially invaluable resource for diseases which are highly heterogeneous.

Biomarkers for Clinical Development

Accelerating Drug Approval with Simoa®: Ultrasensitive Measurement of Biomarkers

Milena Dumont Milutinovic, Senior Manager of Field Applications at Quanterix, walks through the company's ultrasensitive biomarker assay technology.

Biomarkers for Drug Discovery & Development

Selection Biomarkers: Shaping the Future of Drug Development and Regulatory Approval

While constraints on the integration of NGS approaches in selection biomarker validation for new treatments still need ironing out, their benefits in assisting clinical trial progress are undeniable.

Biomarkers for Clinical Development

Multimodal Biomarkers: How Screening Approaches Can Benefit From AI

We explore some of the different applications of AI in biomarkers for cancer analysis, including in urology and the characterisation of prostate cancer.

Biomarkers for Drug Discovery & Development

The Potential Uses of AI in Biomarker Discovery and Biomarker Validation

With efforts already being made to apply artificial intelligence to imaging data for improved biomarker validation, AI is here to stay. However, to truly streamline drug development it needs to be implemented practically.

Biomarker Technologies

ALMAC - Consensus Gene Expression Analysis to Identify Key Hallmarks of Cancer in Malignant Melanoma

Biomarker Technologies

Almac Diagnostic Services - Always a Move Ahead in Precision Medicine

Biomarker Technologies

Almac Dx - claraT Brochure - New Content and Functionality

Biomarker Technologies

Almac Dx - Consensus Gene Expression Analysis to Identify Key Hallmarks of Cancer in Maglignant Melanoma

Biomarker Technologies

Almac Dx Illumina TruSight Oncology 500 ctDNA

Biomarker Technologies

APIS Bioinformatics and Software Development Solutions

Biomarker Technologies

APIS Breast Cancer Subtyping Kit

Biomarker Technologies

APIS Clickmer Systems - Synthetic Antibody Analogues

Biomarker Technologies

APIS Contract Assay Development and Manufacturing

Biomarker Technologies

APIS Overview and Capabilities

Biomarker Technologies

ARC Regulatory - From Lab to Life

Biomarker Technologies

Biorelate - Pharmacodynamic Biomarker Case Study

Biomarker Technologies

CellCarta - Partner with Experts in Precision Medicine

Biomarker Technologies

COMET - High-Throughput Hyperplex Immunofluorescence Made Easy

Biomarker Technologies

Conferma TNF-Alpha Dynamic Detection

Biomarker Technologies

FMP - Multi-Omics Biomarkers R&D and Clinical Testing

Biomarker Technologies

FMP HTG EdgeSeq Technology

Biomarker Technologies

FMP Olink Services - Biomarker Solutions from Discovery to Clinical Qualification

Biomarker Technologies

Galactic Data - Successfully Understanding the Innovations of the Future

Biomarker Technologies

Gryolab - Selective and Robust Biomarker Quantification

Biomarker Technologies

Gyrolab - Bioaffy-4000 CD

Biomarker Technologies

Gyrolab - Biomarker Kit Reagents

Biomarker Technologies

Gyrolab - Compliance with GxP Requirements

Biomarker Technologies

Gyrolab Kits and Solutions

Biomarker Technologies

Gyrolab Systems - Market Validated for Accelerating Biopharmaceutical Development and Production

Biomarker Technologies

Gyros Protein Technologies - Extended Sensitivity for PK and Biomarker Analysis

Biomarker Technologies

Inoviv Overview - Unbiased Identification of Patient Signatures

Biomarker Technologies

Inoviv-Charité Predictive COVID-19 Disease Severity Test

Biomarker Technologies

Merck - Accuracy in Forensic Testing

Biomarker Technologies

Merck - Analysis of Oligonucleotide Standard 6 LC-UV

Biomarker Technologies

Merck - Clinical Capabilities Testing Laboratories

Biomarker Technologies

Merck - Clinical Testing Essentials

Biomarker Technologies

Merck - Create Your Own Column Chemistry

Biomarker Technologies

Merck - High Throughput Glycoprofiling Rituximab Applications

Biomarker Technologies

Merck - Illuminate Your Assay Performance

Biomarker Technologies

Merck - Middle-Up Mass Analysis Protease Digested Cetuximab

Biomarker Technologies

Merck - Next Generation Multiplex Platform

Biomarker Technologies

Merck - Rapid and Robust Protein Chromatography

Biomarker Technologies

Merck - Released N-Linked Glycan Analysis of Adalimumab

Biomarker Technologies

Merck - Safety and Quality in Forensic Testing Capabilities

Biomarker Technologies

Merck - Striving for the Ideal Immunoassay

Biomarker Technologies

Merck - Supel Carbon LC-MS MS Analysis 20 Underivatized Amino Acids

Biomarker Technologies

Merck - Tools for Bioanalysis

Biomarker Technologies

Merck - Workflow for the Analysis of Polysorbate 80

Biomarker Technologies

Merck Millipore - All-In-One Interferon Testing

Biomarker Technologies

Merck Millipore - Bigger, Better Cytokine Analysis

Biomarker Technologies

Merck Millipore - Expand Your Immune Checkpoint Research by Multiplexing Your Mouse Tumour Models

Biomarker Technologies

Merck Millipore - Multiplexed Evaluation of Soluble Immune Checkpoint Molecules

Biomarker Technologies

Merck Millipore - Simultaneous Quantitative Profiling of 48 Immune Factors

Biomarker Technologies

Merck Millipore - Thorough Washing and Consistent Performance

Biomarker Technologies

Merck Millipore Toxicity Panels - From Compound to Drug

Biomarker Technologies

MILLIPLEX Human Cytokine Panel: A Lot to Lot Consistency of Cytokine Measurement

Biomarker Technologies

Optimer - Accelerating Your Journey to the Clinic

Biomarker Technologies

Optimer - Drug Conjugates

Biomarker Technologies

Optimer - Enabled Small Molecule Detection and Analysis

Biomarker Technologies

Optimer Diagnostic Reagent COVID-19 Datapack

Biomarker Technologies

Supelco - BIOshell Peptide Mapping Trastuzumab UHPLC-MS

Biomarker Technologies

Supelco - Supel Carbon N-Glycan Human IgG

Biomarker Technologies

The Optimer Discovery Platform

Biomarker Technologies

Whole Exome Sequencing (WES) Data Generation Service

Biomarkers for Clinical Development

Surrogate Biomarkers in NASH and Liver Cirrhosis: Qualifying for Clinical Trial Validation and Legislative Success

Highly involved treatment scenarios and prognostics are required to properly assess best-practice approaches for investigating issues posed by NASH and liver cirrhosis. Surrogate biomarkers present a less invasive approach to assessing these outcomes.

Diagnostics

Emergency Use Authorization Issued by FDA for Mpox Virus DNA Test

EUAs exist under FDA regulation to improve the availability of medical countermeasures, such as vaccines and diagnostic tests, during public health emergencies. With future pandemics a tangible possibility, further EUAs for other PCR tests and vaccines are all but certain.

Genomic Markers & Precision Medicine

Clinical Biomarker Trends to Watch in 2023

The identification of novel clinical biomarkers is set to continue, with further research and investment in fields such as next-gen sequencing and miRNA targeting.

Biomarkers for Clinical Development

Keytruda sees Trial Success in Treating Endometrial Cancer Patients

The immunotherapeutic was successfully trialled in patients with endometrial cancer, the results of which Merck said it would discuss with regulatory authorities.

Biomarkers for Clinical Development

Eli Lilly Focus on Phase III Trial for Alzheimer’s Treatment Following FDA Fast Lane Setback

The FDA ‘specifically requested’ data from at least 100 patients who received a minimum 12 months’ treatment of Lilly’s drug donanemab before the approval process could progress further.

Biomarkers for Clinical Development

FDA Approves Merck-Developed KEYTRUDA for Non-Small Cell Lung Cancer Therapy

KEYTRUDA demonstrated a clinically meaningful improvement in disease-free survival in patients following surgical resection and platinum-based chemotherapy.

Biomarkers for Drug Discovery & Development

Bioassay Optimisation: How the Pandemic Reshaped International Standards for New Therapeutics

The global race to develop, trial, and distribute a vaccine for Covid-19 may have permanently accelerated the development of future therapeutics, including treatments for cancer.

Biomarkers for Clinical Development

FDA Commits to Increasing Diversity in Clinical Trials

The move follows steps announced by the EMA and the MHRA to ensure clinical trials are more reflective of patient populations.

Biomarkers for Clinical Development

Predicting Parkinson’s Disease with Machine Learning

Understanding machine learning’s role in providing a biomarker for the neurological condition.

Diagnostics

Study Reveals Altered Spontaneous Brain Activity in People with Down Syndrome

A new study has revealed that using functional magnetic resonance techniques shows the differences in the spontaneous activity of the brain in people with Down syndrome compared to the general population.

Diagnostics

The Ethical Issues of Pre-Emptive Dementia Diagnosis

If you were at risk of developing Alzheimer’s disease, would you want to know?

Diagnostics

Low-Cost Method for Cancer Testing

The Heatrich-BS assay is a novel low-cost sequencing method for low-cost cancer testing.

Diagnostics

Functional Cure Biomarker for Hepatitis B Virus

Study suggests the haplotype number for hepatitis B virus could act as a predictive biomarker for functional cure during antiviral therapies.

Diagnostics

Can Protein Shapes Indicate Parkinson's Disease?

The first ever potential biomarker for Parkinson’s disease has been discovered.

Diagnostics

Urinary Biomarker Detects Early Onset of Alzheimer’s Disease

Discovery of a new sensitive urinary biomarker could pave the way for cost-effective and large-scale screening of neurodegenerative disease.

Diagnostics

Diagnostic Biomarkers Discovered for Lyme Disease

New hope raised for the early detection and treatment of the tick-borne illness.

Diagnostics

Predicting Heart Disease Risk with ‘Good’ Cholesterol: Is it Still Viable?

A new study analysing the cholesterol levels of black adults challenges traditional perceptions of its role in predicting heart disease risk.

Biomarker Technologies

Breath Biopsy Omni For Comprehensive & Reliable Detection Of VOC Biomarkers In Breath

On-Demand Webinar featuring Dr Elizabeth Crone, Business Development Manager at Owlstone & Dr Hsuan (Tina) Chou, Biomarker Scientist at Owlstone

Biomarkers for Clinical Development

Toxicity Markers of Cognitive Deterioration in Young Cancer Sufferers

Cancer-related cognitive impairment in young adults found pre-treatment, study reports.

Biomarker Technologies

Are Neuroimmune Proteins the Key to Neurodegenerative Disease Diagnosis?

Unique neuroinflammatory signatures and pathways present in tauopathies could provide greater insight into distinct mechanisms of disease.

Biomarkers for Clinical Development

Implementing Patient-Centricity into Biomarker Clinical Trials

How can we better define patient-centric clinical trials within the drug development process?

Biomarkers for Clinical Development

Cervical Indicators of HIV Risk Found

Study finds predictive link between genital herpes and HIV.

Diagnostics

Predicting Preeclampsia Risk with Placental Proteins

A new study by Cedars-Sinai could identify protein biomarkers for preeclampsia.

Biomarkers for Clinical Development

Novel Microbial Immunotherapies for Bladder Cancer Treatment

The potential oncolytic applications of Salmonella ZH9 include its use in mitigating diseases such as bladder cancer, with a demonstrated therapeutic effect in cancer models.

Biomarkers for Clinical Development

Patient Engagement in Biomarker Development

Christopher Conn, Director of Diagnostics Strategy at Amgen, leads a Discussion Group on patient testing and engagement in biomarker clinical trials.

Biomarker Technologies

Biomarker Testing Consolidation and Implementation Using Multiplex Immunofluorescence

Multiplex immunofluorescence is gaining prevalence in oncology diagnostics; what makes it so effective, and how is it being brought into the clinic?

Biomarkers for Clinical Development

Biomarkers for NASH Symposium: Most Anticipated Presentation

Discover key event highlights from Oxford Global's upcoming Biomarkers for NASH Symposium 2022.

Biomarkers for Clinical Development

Scientists at Stanford Medicine Predict Who Will Develop Vaccine Immunity

A gene signature found in antibody-producing cells could accelerate vaccine development.

Biomarkers for Drug Discovery & Development

New Therapeutic Target for Aggressive Breast Cancer

Scientists at VCU Massey Cancer Center pinpoint druggable target in aggressive breast cancer.

Digital Biomarkers & Digital Pathology

Digital Biomarkers for Disease Detection and Monitoring

Beverley Patterson, Clinical Science Director at Ono Pharma UK Ltd, leads a Discussion Group on harnessing biomarker technologies to improve disease detection and tracking.

Diagnostics

Genetic Variants Linked to Dyslexia

A new study from the University of Edinburgh has identified potential gene indications associated with dyslexia.

Oxford Global's R&D Key 40 Stories 2022

Download a copy of the R&D Key 40 Stories 2022 eBook today

Diagnostics

Thirdhand Smoke Triggers Skin Disease

New research suggests acute exposure to thirdhand smoke elevates biomarkers associated with skin diseases.

Digital Biomarkers & Digital Pathology

Digital Biomarkers: Using Smartphones for the Passive Monitoring of Neurodegenerative Diseases

Smartphones, laptops and other household electronic devices could be optimised for the early detection of neurodegenerative diseases such as Alzheimer’s. Preventative monitoring approaches such as these could provide another avenue of detection to abet the provision of treatment.

Diagnostics

Towards Improved Biomarker Analysis and Validation

Key opinion leaders talk understanding the scientific and regulatory considerations for the qualification of biomarkers.

Diagnostics

New Gene Target Discovered for Aggressive Lung Cancer

Scientists at Northwestern Medicine propose a potential biomarker for identifying small-cell lung cancer.

Biomarker Technologies

Biomarker Discovery Platform - Sapient

Biomarker Technologies

FlexVUE Multiplexed Immunofluorescence Assays - Ultivue

Biomarkers for Clinical Development

Human Biology Database - Sapient

Biomarker Technologies

ID3EAL™ miRNA Knowledge Panels - MiRXES

Biomarkers for Drug Discovery & Development

Indivumed Biobank

Genomic Markers & Precision Medicine

Liquid Biopsy (Longitudinal Cell-free Plasma) - Indivumed

Biomarker Technologies

RNA Sequencing - MiRXES

Genomic Markers & Precision Medicine

Spatial Transcriptomics Services - Indivumed

Biomarker Technologies

Whole Exome Sequencing - MiRXES

Biomarker Technologies

Whole Genome Bisulphite Sequencing - MiRXES

Biomarker Technologies

Whole Genome Sequencing - MiRXES

Biomarkers for Clinical Development

Non-Invasive Biomarkers: Aiding Clinical Qualification of Prognostics and Monitoring Biomarkers for Liver Cirrhosis

In this Commentary, we explore how non-invasive biomarkers may be used to diagnose pre-symptomatic NASH in patients without them undergoing invasive biopsies.

Biomarkers for Clinical Development

The Applicability of Clinical Biomarkers for NASH and Fibrosis

Archana Vijayakumar, Senior Research Scientist I of Fibrosis at Gilead, presents on understanding disease progression and therapeutic efficacy in preclinical models for NASH.

Biomarkers for Clinical Development

Overcoming Challenges of NASH in Clinical Development

Vincent Mikol, Precision Medicine Head at Sanofi, leads a discussion on navigating the current challenges of NASH in clinical development.

Biomarkers for Drug Discovery & Development

Treating the Untreatable: Unlocking Precision Medicine Biomarkers for NASH

Introducing PreciNASH, a multidisciplinary consortium strengthening the link between research outputs and clinical applications in NASH disease treatment.

Digital Biomarkers & Digital Pathology

Identifying Prognostic Biomarkers for Follicular Lymphoma

How can the spatial interactions of the tumour immune microenvironment reveal prognostic insights into Follicular Lymphoma? We ask Martin Fergie, Lecturer in Healthcare Sciences at the University of Manchester.

Biomarkers for Clinical Development

The Biomarker Factory: A High-Performance Analytical Platform for Fluid Biomarker Development, Validation, and Measurement

Amanda Heslegrave, Senior Research Fellow at the UK Dementia Research Centre, UCL, showcases cutting-edge super sensitive immunoassay research at Biomarkers UK 2021.

Biomarker Technologies

GOAL: A Collaborative Approach to Next Generation Sequencing in Oncology and Beyond

The Genomics Organisation for Academic Laboratories – known also to the world as GOAL – is a collaborative project set up by a group of academic centres across the United States to facilitate affordable next generation sequencing. The long-term target is to expand patient access to personalised genomic testing, as well as future biomarker discovery.

Biomarker Technologies

Enabling Precision Oncology with Tumour Profiling Solutions

Erin Newburn, Senior Director, Field Applications Scientist at Personalis, Inc. showcases the Personalis NeXT Platform ®, a tumour profiling solution for both tissue and liquid biopsies at Biomarkers UK 2022.

Genomic Markers & Precision Medicine

Current Status of Omics-Based Biomarkers

Anna Lyubetskaya, Senior Principal Scientist at Bristol Myers Squibb, leads a discussion on the industry landscape and ‘Current Status of Omics-Based Biomarkers.’

Biomarkers for Clinical Development

Quantitative Mass Spectrometry: a Clinical Tool for Biomarker Discovery and Qualification

Quantitative mass spectrometry offers a clinical tool for the discovery of biomarkers, which can be vital in helping to treat certain cancers. In this Commentary article, we explore the applications of mass spectrometry for the identification of triple negative breast cancer and some of the implications for future research.

Biomarker Technologies

Unlocking the Potential of Spatial Multi-Omics and Cytometry

Senior representatives from Ultivue, Genentech, and GSK discuss the current trends and opportunities in enabling the future of multi-omics-based analysis.

Biomarker Technologies

Spatial Biomarkers & Multiplexed Immunofluorescence in Immuno-Oncology

Yu Liang, Director of Clinical Biomarkers at Compugen, leads a discussion on ‘Spatial Biomarkers & Multiplexed Immunofluorescence in Immuno-Oncology.’

Biomarkers for Drug Discovery & Development

What’s Next for Predictive Biomarkers in Immunotherapy?

From maximising immune response with combination biomarkers to conducting diagnostic innovation in immunotherapy prognosis, the future of predictive biomarkers is fast approaching. We speak to senior representatives from industry and academia to find out more.

Biomarkers for Drug Discovery & Development

Developing a biomarker? Keep these 3 takeaways in mind

Three key take aways when you develop biomarkers: one during biomarker discovery, one during biomarker development and one during biomarker validation.

Biomarkers for Drug Discovery & Development

The 5 most common pitfalls when developing biomarkers

Discovering a strong biomarker is an expensive and time-consuming process. One of the key takeaways is to take your time and look at the data before you start testing for biomarkers.

Biomarkers for Drug Discovery & Development

The future of biomarkers: where are they heading?

Biomarkers come in many shapes and sizes. It’s an ever-evolving subject with many under-discovered possibilities. Let’s look at some ways biomarkers are looking to evolve.

Biomarker Technologies

A True Manchester Partnership Advancing Precision Medicine

Biomarker Technologies

ACROBiosystems: Where Proteins and Innovation Advance Biomedicine

Biomarker Technologies

Advancing Liquid Biopsy Assays into Clinical Routine

Genomic Markers & Precision Medicine

Almac Diagnostic Services: Always a Move Ahead in Precision Medicine

Biomarker Technologies

Almac Group: Consensus Gene Expression Analysis to Identify Key Hallmarks of Cancer in Malignant Melanoma

Biomarker Technologies

Almac Group: Suitability Assessment and Performance Evaluation

Biomarker Technologies

Almac Group: Whole Exome Sequencing (WES) Data Generation Service

Digital Biomarkers & Digital Pathology

Applying AI to Automate Biomarker Identification

Biomarker Technologies

BOND RX Fully Automated IHC, ISH & Emerging Tests

Biomarkers for Clinical Development

CellCarta: Accelerate the Development and Approval of Your Cell Therapy Program

Digital Biomarkers & Digital Pathology

CellCarta: Data Powered Pathology

Biomarker Technologies

Chromogenic Multiplexing Detection Portfolio

Biomarker Technologies

CLARA: Total mRNA Report

Biomarker Technologies

Denovo: Bringing Liquid Biopsies to Clinical Practice

Biomarker Technologies

Drug profiling using Human Precision Cut Cancer Tissue Slices

Biomarker Technologies

FLEXMAP 3D: Multiplexing Solution for Proteins and Nucleic Acids

Biomarkers for Drug Discovery & Development

Indivumed Biobank

Biomarker Technologies

Indivumed: Liquid Biopsy

Biomarker Technologies

Leica Biosystems: Aperio GT

Biomarker Technologies

Luminex 200: Multiplexing Solution for Proteins and Nucleic Acids

Biomarker Technologies

Merck: ISOTEC® Stable Isotopes

Biomarker Technologies

Merck: miR-122 Liver Injury Detection Assay

Biomarker Technologies

Multiplexed Evaluation of Soluble Immune-Checkpoint Molecules in Sera from Metastatic NSCLC Patients Receiving Immunotherapy

Biomarker Technologies

NavigAID: Harnessing the Utility of Auto Antibodies

Biomarker Technologies

NeoGenomics: Commercial Considerations for a Successful CDx

Biomarker Technologies

NeoGenomics: Global Capabilities

Biomarker Technologies

Simultaneous Quantitative Profiling with MILLIPLEX®

Biomarker Technologies

SMCxPRO® Immunoassay System

Biomarker Technologies

TruCulture Catalogue

Biomarker Technologies

xMAP INTELLIFLEX Systems

Biomarker Technologies

xMAP Technology: Products and Services Catalogue

Biomarkers for Clinical Development

Cultivating Neuro-Organoids for Translational Research

Key opinion leaders from GlaxoSmithKline and Weill Cornell Medicine discuss future perspectives on neuro-organoids.

Biomarkers for Clinical Development

Fluid Biomarkers for Neurodegenerative Disease

Jordi Clarimon, Lead Specialist in Fluid Biomarkers at Lundbeck, leads a discussion on ‘Fluid Biomarkers for Neurodegenerative Diseases.'

Diagnostics

Human Stem Cell Models of Neurodegeneration: Exploiting In Vitro Phenotypes to Support Drug Delivery

In this Commentary article, we investigate the applications of human stem cell modelling for identifying the ways in which neurodegenerative diseases such as Alzheimer's and Parkinson's affect the brain.

Digital Biomarkers & Digital Pathology

Pathway Mining and Proliferation Markers: Refining the Identification of Cancers for Systemic Treatments Through Building Digital Twins of Disease Pathways

This Commentary article explores the applications of pathway mining for the identification of disease targets associated with breast cancer, where there is an unmet need for treatment. The mission is to identify the best proliferation marker for guiding the choice of systemic treatments for breast cancer.

Biomarkers for Clinical Development

Translational Biomarkers to Guide Clinical Development of CAR T-Cells

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our March Discussion Group addressing ‘Translational Biomarkers to Guide Clinical Development of CAR T-Cells’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

Diagnostics

Disruptive Innovation in Diagnostics

Data management for diagnostic devices is fast becoming a vital concern of the biomarkers industry. With the increased prevalence of ML and AI, this article interviews key opinion leaders from Nottingham Trent University, Apis Assay Technologies, and UCB about the future perspectives of diagnostic innovation and regulation.

Biomarkers for Clinical Development

Using Biomarkers For Clinical Development and Regulatory Approval

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our February Discussion Group, focusing on ‘Using Biomarkers For Clinical Development & Regulatory Approval,’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

Biomarkers for Clinical Development

Transforming Clinical Development with Biomarkers

How can the industry transform itself with improved biomarkers for clinical development? And what hurdles stand in the way? We sat down with senior representatives from Galapagos, Ohio State University, and Genentech to find out more.

Biomarkers for Clinical Development

The Patient-focused ‘Paradigm Shift’ That Could ‘Revolutionise’ Clinical Trials

Melanie Anderson, Principal Scientist at MSD, on how the pandemic has made scientists rethink clinical trials.

Biomarker Technologies

Implementing Flow Cytometry Assays In Biomarker Research

Oxford Global’s Discussion Groups provide a focused networking opportunity for a select group of like-minded experts on a monthly basis. Our first Biomarkers Discussion Group addressing ‘Implementing Flow Cytometry Assays In Biomarker Research’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

Digital Biomarkers & Digital Pathology

Digital Biomarkers – An Industry Game Changer

This commentary article looks at the latest applications in digital and wearable biomarkers, with industry and academic insights from GlaxoSmithKline, Roche, and University College London.

Digital Biomarkers & Digital Pathology

Overcoming the Regulatory Challenges of Digital Health Technologies

Dr Derek Hill, Professor of Digital Health at University College London, on making the most of digital biomarkers and achieving clinical endpoints.

Diagnostics

Non-invasive Early Disease Detection and Precision Medicine Using Breath Biomarkers

Breath is the ideal biomarker matrix for the future of diagnostics. Sample collection is non-invasive, painless and easy to perform, and breath is a rich source of potential biomarkers. Potential applications for breath tests include disease detection, phenotyping, progression and treatment monitoring, and complementary diagnostics. Discover the benefits and capabilities of breath testing, and start researching breath biomarkers with Breath Biopsy®.

In-Person & Online Events

Online Activities

Speakers

Sponsors

Media Partners

Digital Services

Lead Generation Dinners

Content Services

Event Management

Browse All Resources

Filter by Subject Area

Latest Resources

Resources

Top R&D Stories of 2023